Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth

Sep 26, 2011, 04:20 ET from Reportlinker

NEW YORK, Sept. 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth

http://www.reportlinker.com/p0629401/Immunoglobulins-Market-to-2017---Off-Label-Usage-and-Treatment-of-Primary-Immunodeficiency-Diseases-and-Neurological-Disorders-Stimulate-Market-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth

Summary

GBI Research's report, "Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth" provides in-depth analysis of the, drivers and barriers that affect the global immunoglobulins market. The report analyzes the markets for immunoglobulins products in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Epidemiology, revenue, and annual cost of therapy are forecast until 2017 for the key geographies as well as seven key therapeutic segments. The report also provides profiles for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

Scope

The scope of this report includes -

- Annualized market data for the immunoglobulins market from 2002 to 2010, and forecast to 2017.

- Analysis of the seven key therapeutic segments. These include PID, CIDP, multifocal motor neuropathy, myasthenia gravis, chronic lymphocytic leukemia, guillain-barre syndrome and idiopathic thrombocytopenic purpura.

- Analysis of the immunoglobulins markets in the leading geographies of the world, which include the US, the top five countries in Europe and Japan.

- Market characterization of the immunoglobulins (PID, CIDP, multifocal motor neuropathy, myasthenia gravis, chronic lymphocytic leukemia, guillain-barre syndrome and idiopathic thrombocytopenic purpura) market, including market size, revenue analysis by the top seven geographies, annual cost of therapy, and epidemiology.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of the pipeline molecules in various phases of drug development.

- Competitive profiling of the leading companies. The key companies studied in this report are Baxter International Inc., Biotest, Bio Products Laboratory Ltd., CSL Behring LLC, Kedrion, LFB, Octapharma, Talecris, and Grifols.

- Key M&A activities and licensing agreements between 2004 and 2011 in the global immunoglobulins market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Develop key strategic initiatives by understanding the key focus areas of the leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 7

1.2 List of Figures 9

2 Global Immunoglobulins Market: Introduction 11

2.1 Overview 11

2.2 GBI Research Report Guidance 12

3 Global Immunoglobulins Market: Market Overview 13

3.1 Introduction 13

3.1.1 Rising Demand for Immunoglobulins Attributed to New Indications 14

3.1.2 On-Label Uses versus Off-Label Uses in the US 15

3.1.3 IVIG vs. SCIG Usage 15

3.2 Revenue Forecasts for the Global Immunoglobulins Market 16

3.3 Annual Cost of Therapy 18

3.4 Immunoglobulins Market Drivers and Restraints 19

3.4.1 Immunoglobulins Market Drivers 20

3.4.2 Immunoglobulins Market Restraints 20

4 Global Immunoglobulins Market: Geographical Landscape 21

4.1 Geographical Break-up 21

4.1.1 The US 22

4.1.2 Top Five Countries in Europe 24

4.1.3 Japan 27

5 Global Immunoglobulins Market: Therapeutic Landscape 29

5.1 Primary Immunodeficiency 29

5.1.1 Introduction 29

5.1.2 Revenue 30

5.1.3 Annual Cost of Therapy 32

5.1.4 Epidemiology 33

5.1.5 Current Use 36

5.1.6 Geographical Segmentation 37

5.2 Guillain-Barré Syndrome Market 39

5.2.1 Introduction 39

5.2.2 Revenue 40

5.2.3 Annual Cost of Therapy 41

5.2.4 Epidemiology 42

5.2.5 Current Use 44

5.2.6 Geographical Segmentation 45

5.3 Chronic Lymphocytic Leukemia Market 47

5.3.1 Introduction 47

5.3.2 Revenue 48

5.3.3 Annual Cost of Therapy 49

5.3.4 Epidemiology 50

5.3.5 Current Use 54

5.3.6 Geographical Segmentation 55

5.4 Chronic Inflammatory Demyelinating Polyneuropathy Market 56

5.4.1 Introduction 56

5.4.2 Revenue 57

5.4.3 Annual Cost of Therapy 58

5.4.4 Epidemiology 59

5.4.5 Current Use 61

5.4.6 Geographical Segmentation 62

5.5 Myasthenia Gravis Market 63

5.5.1 Introduction 63

5.5.2 Revenue 64

5.5.3 Annual Cost of Therapy 65

5.5.4 Epidemiology 66

5.5.5 Current Use 68

5.5.6 Geographical Segmentation 69

5.6 Multifocal Motor Neuropathy Market 70

5.6.1 Introduction 70

5.6.2 Revenue 71

5.6.3 Annual Cost of Therapy 72

5.6.4 Epidemiology 74

5.6.5 Current Use 77

5.6.6 Geographical Segmentation 78

5.7 Idiopathic Thrombocytopenic Purpura 79

5.7.1 Introduction 79

5.7.2 Revenue 80

5.7.3 Annual Cost of Therapy 81

5.7.4 Epidemiology 82

5.7.5 Current Use of Immunoglobulins and Other Therapies 85

5.7.6 Geographical Segmentation 85

6 Global Immunoglobulins Market: Pipeline Analysis 87

6.1 Research and Development Pipeline – CIDP 87

6.2 Research and Development Pipeline – PID 87

6.3 Research and Development Pipeline – GBS 88

6.4 Research and Development Pipeline – ITP 88

6.5 Research and Development Pipeline – Myasthenia Gravis 88

6.6 Research and Development Pipeline – Multifocal Motor Neuropathy 88

6.7 Research and Development Pipeline – CLL 88

7 Global Immunoglobulins Market: Profiles of Marketed Products 89

7.1 Privigen 89

7.1.1 Overview 89

7.1.2 Approved Indications 89

7.1.3 Safety 89

7.1.4 Efficacy 89

7.1.5 Clinical Study Details 90

7.2 Gammagard S/D 90

7.2.1 Overview 90

7.2.2 Approved Indications 90

7.2.3 Safety 91

7.2.4 Efficacy 91

7.3 Gammagard Liquid 91

7.3.1 Overview 91

7.3.2 Approved Indications 92

7.3.3 Safety 92

7.3.4 Efficacy 92

7.3.5 Clinical Study Details 92

7.4 Octagam 5% 92

7.4.1 Overview 92

7.4.2 Approved Indications 93

7.4.3 Safety 93

7.4.4 Efficacy 93

7.5 Flebogamma 5% 93

7.5.1 Overview 93

7.5.2 Safety 93

7.5.3 Efficacy 94

7.6 Flebogamma 10% 94

7.6.1 Overview 94

7.6.2 Safety 94

7.6.3 Efficacy 94

7.7 Gamunex 95

7.7.1 Overview 95

7.7.2 Safety 95

7.7.3 Efficacy 95

7.8 Gammaplex 96

7.8.1 Overview 96

7.8.2 Safety 96

7.8.3 Efficacy 97

7.8.4 Clinical Study Details 97

7.9 Vivaglobin 97

7.9.1 Overview 97

7.9.2 Safety 97

7.9.3 Efficacy 97

7.10 Hizentra 98

7.10.1 Overview 98

7.10.2 Safety 98

7.10.3 Efficacy 98

7.11 Pentaglobin 98

7.11.1 Overview 98

7.11.2 Efficacy 98

7.11.3 Safety 99

7.12 Tegeline 99

7.12.1 Overview 99

7.12.2 Efficacy in multifocal motor neuropathy 99

7.12.3 Safety in multifocal motor neuropathy 99

7.12.4 Efficacy in CIDP 99

7.12.5 Safety in CIDP 99

8 Global Immunoglobulins Market: Competitive Landscape 100

8.1 Market Share Analysis: Immunoglobulins 100

8.2 Baxter International Inc. 101

8.2.1 Business Description 101

8.2.2 SWOT Analysis 101

8.3 Biotest 102

8.3.1 Business Description 102

8.3.2 SWOT Analysis 102

8.4 Bio Products Laboratory Ltd. 103

8.4.1 Business Description 103

8.4.2 SWOT Analysis 103

8.5 CSL Behring LLC 103

8.5.1 Business Description 103

8.5.2 SWOT Analysis 104

8.6 Kedrion S.p.A. 104

8.6.1 Business Description 104

8.6.2 SWOT Analysis 105

8.7 LFB S.A. 105

8.7.1 Business Description 105

8.7.2 SWOT Analysis 105

8.8 Octapharma AG 106

8.8.1 Business Description 106

8.8.2 SWOT Analysis 106

8.9 Talecris Biotherapeutics Holdings Corp 107

8.9.1 Business Description 107

8.9.2 SWOT Analysis 107

8.10 Grifols S.A. 108

8.10.1 Business Description 108

8.10.2 SWOT Analysis 108

9 Global Immunoglobulins Market: M&A and Licensing Deals Landscape 109

9.1 Overview 109

9.2 R&D Licensing Agreements 112

9.2.1 Kedrion Signs Up With Prometic for Access to the Latter's Technologies to Manufacture Hyperimmunes in Europe 112

9.2.2 WIBP Enters Into Licensing Agreement with Prometic for the Latter's PPP System to Produce Plasma-Derived Products in China 112

9.3 Co-Development Agreements 113

9.3.1 Baxter Collaborates With Halozyme Baxter for a Subcutaneous Route of Administration of GAMMAGARD LIQUID 10% 113

10 Global Immunoglobulins Market: Appendix 114

10.1 Market Definitions 114

10.2 Abbreviations 114

10.3 Research Methodology 116

10.3.1 Coverage 116

10.3.2 Secondary Research 116

10.3.3 Primary Research 117

10.3.4 Therapeutic Landscape 117

10.3.5 Market Size by Geography 119

10.3.6 Geographical Landscape 120

10.3.7 Pipeline Analysis 120

10.3.8 Competitive Landscape 120

10.3.9 Expert Panel Validation 120

10.4 Contact Us 120

10.5 Disclaimer 121

10.6 Sources 1211.1 List of Tables

Table 1: Immunoglobulins Market, Global, Consumption of IVIG, 1990-2006 14

Table 2: Immunoglobulins Market, Global, Consumption of IVIG, 2006-2016 14

Table 3: Immunoglobulins Market, Global, Revenue ($m), 2002-2010 17

Table 4: Immunoglobulins Market, Global, Revenue ($m), 2010-2017 17

Table 5: Immunoglobulins Market, Global, Annual Cost of Therapy ($), 2002-2010 19

Table 6: Immunoglobulins Market, Global, Annual Cost of Therapy ($), 2010-2017 19

Table 7: Immunoglobulins Market, The US, Revenue ($m), 2002-2010 22

Table 8: Immunoglobulins Market, The US, Revenue ($m), 2010-2017 22

Table 9: Immunoglobulins Market, The US, Annual Cost of Therapy ($), 2002-2010 23

Table 10: Immunoglobulins Market, The US, Annual Cost of Therapy ($), 2010-2017 23

Table 11: Immunoglobulins Market, Top Five Countries in Europe, Revenue, ($m), 2002-2010 24

Table 12: Immunoglobulins Market, Top Five Countries in Europe, Revenue, ($m), 2010-2017 25

Table 13: Immunoglobulins Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010 26

Table 14: Immunoglobulins Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017 26

Table 15: Immunoglobulins Market, Japan, Revenue ($m), 2002-2010 27

Table 16: Immunoglobulins Market, Japan, Revenue ($m), 2010-2017 27

Table 17: Immunoglobulins Market, Japan, Annual Cost of Therapy, ($), 2002-2010 28

Table 18: Immunoglobulins Market, Japan, Annual Cost of Therapy, ($), 2010-2017 28

Table 19: Immunoglobulins Market, Global, Primary Immunodeficiency, Revenue ($m), 2002-2010 30

Table 20: Immunoglobulins Market, Global, Primary Immunodeficiency, Revenue ($m), 2010-2017 30

Table 21: Immunoglobulins Market, Global, Primary Immunodeficiency, Annual Cost of Therapy ($), 2002-2010 32

Table 22: Immunoglobulins Market, Global, Primary Immunodeficiency, Annual Cost of Therapy ($), 2010-2017 32

Table 23: Immunoglobulins Market, Global, Primary Immunodeficiency, Epidemiology, 2002-2010 34

Table 24: Immunoglobulins Market, Global, Primary Immunodeficiency, Epidemiology, 2010-2017 34

Table 25: Immunoglobulins Market, Global, Primary Immunodeficiency, Geographical Segmentation of Revenue, ($m), 2002-2010 37

Table 26: Immunoglobulins Market, Global, Primary Immunodeficiency, Geographical Segmentation of Revenue, ($m), 2010-2017 38

Table 27: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Revenue ($m), 2002-2010 40

Table 28: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Revenue ($m), 2010-2017 40

Table 29: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Annual Cost of Therapy ($), 2002-2010 41

Table 30: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Annual Cost of Therapy ($), 2010-2017 41

Table 31: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Epidemiology, 2002-2010 42

Table 32: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Epidemiology, 2010-2017 43

Table 33: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Geographical Segmentation of Revenue, ($m), 2002-2010 46

Table 34: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Geographical Segmentation of Revenue, ($m), 2010-2017 46

Table 35: Immunoglobulins Market, Global, CLL, Revenue, ($m), 2002-2010 48

Table 36: Immunoglobulins Market, Global, CLL, Revenue ($m), 2010-2017 48

Table 37: Immunoglobulins Market, Global, CLL, Annual Cost of Therapy ($), 2002-2010 49

Table 38: Immunoglobulins Market, Global, CLL, Annual Cost of Therapy ($), 2010-2017 49

Table 39: Immunoglobulins Market, Global, CLL, Epidemiology, ('000), 2002-2010 50

Table 40: Immunoglobulins Market, Global, CLL, Epidemiology, ('000), 2010-2017 51

Table 41: Immunoglobulins Market, Global, CLL, Geographical Segmentation of Revenue, ($m), 2002-2010 55

Table 42: Immunoglobulins Market, Global, CLL, Geographical Segmentation of Revenue, ($m), 2010-2017 56

Table 43: Immunoglobulins Market, Global, CIDP, Revenue, ($m), 2002-2010 57

Table 44: Immunoglobulins Market, Global, CIDP, Revenue ($m), 2010-2017 57

Table 45: Immunoglobulins Market, Global, CIDP, Annual Cost of Therapy ($), 2002-2010 58

Table 46: Immunoglobulins Market, Global, CIDP, Annual Cost of Therapy ($), 2010-2017 58

Table 47: Immunoglobulins Market, Global, CIDP, Epidemiology ('000), 2002-2010 59

Table 48: Immunoglobulins Market, Global, CIDP, Epidemiology ('000), 2010-2017 60

Table 49: Immunoglobulins Market, Global, CIDP, Geographical Segmentation of Revenue, ($m), 2002-2010 62

Table 50: Immunoglobulins Market, Global, CIDP, Geographical Segmentation of Revenue, ($m), 2010-2017 63

Table 51: Immunoglobulins Market, Global, Myasthenia Gravis, Revenue, ($m), 2002-2010 64

Table 52: Immunoglobulins Market, Global, Myasthenia Gravis, Revenue ($m), 2010-2017 64

Table 53: Immunoglobulins Market, Global, Myasthenia Gravis, Annual Cost of Therapy ($), 2002-2010 65

Table 54: Immunoglobulins Market, Global, Myasthenia Gravis, Annual Cost of Therapy ($), 2010-2017 65

Table 55: Immunoglobulins Market, Global, Myasthenia Gravis, Epidemiology, 2002-2010 66

Table 56: Immunoglobulins Market, Global, Myasthenia Gravis, Epidemiology, 2010-2017 67

Table 57: Immunoglobulins Market, Global, Myasthenia Gravis, Geographical Segmentation of Revenue, ($m), 2002-2010 69

Table 58: Immunoglobulins Market, Global, Myasthenia Gravis, Geographical Segmentation of Revenue, ($m), 2010-2017 70

Table 59: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Revenue, ($m), 2002-2010 71

Table 60: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Revenue ($m), 2010-2017 71

Table 61: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Annual Cost of Therapy ($), 2002-2010 72

Table 62: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Annual Cost of Therapy ($), 2010-2017 73

Table 63: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Epidemiology, 2002-2010 75

Table 64: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Epidemiology, 2010-2017 75

Table 65: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Geographical Segmentation of Revenue, ($m), 2002-2010 78

Table 66: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Geographical Segmentation of Revenue, ($m), 2010-2017 79

Table 67: Immunoglobulins Market, Global, ITP, Revenue, ($m), 2002-2010 80

Table 68: Immunoglobulins Market, Global, ITP, Revenue ($m), 2010-2017 80

Table 69: Immunoglobulins Market, Global, ITP, Annual Cost of Therapy ($), 2002-2010 81

Table 70: Immunoglobulins Market, Global, ITP, Annual Cost of Therapy ($), 2010-2017 82

Table 71: Immunoglobulins Market, Global, ITP, Epidemiology, 2002-2010 83

Table 72: Immunoglobulins Market, Global, ITP, Epidemiology, 2010-2017 83

Table 73: Immunoglobulins Market, Global, ITP, Geographical Segmentation of Revenue, ($m), 2002-2010 86

Table 74: Immunoglobulins Market, Global, ITP, Geographical Segmentation of Revenue, ($m), 2010-2017 86

Table 75: Immunoglobulins Market, Global, R&D Pipeline in CIDP Market, 2011 87

Table 76: Immunoglobulins Market, Global, R&D Pipeline in CIDP Market, 2011 87

Table 77: Immunoglobulins Market, Global, R&D Pipeline in ITP Market, 2011 88

Table 78: Immunoglobulins Market, Global, R&D Pipeline in Myasthenia Gravis Market, 2011 88

Table 79: Immunoglobulins Market, Global, R&D Pipeline in Multifocal Motor Neuropathy Market, 2011 88

Table 80: Immunoglobulins Market, Global Major M&A Deals, 2004-2010 110

Table 81: Immunoglobulins Market, Global Licensing Deals, 2008 112

Table 82: Immunoglobulins Market, Global Co-Developments, 2005-2007 1131.2 List of Figures

Figure 1: Immunoglobulins Market, Global, Consumption of IVIG, 1990-2016 14

Figure 2: Immunoglobulins Market, Global, Revenue ($m), 2002-2017 17

Figure 3: Immunoglobulins Market, Global, Annual Cost of Therapy ($), 2002-2017 18

Figure 4: Immunoglobulins Market, Global, Drivers and Restraints 19

Figure 5: Immunoglobulins Market, Geographical Break-Up, Revenue (%), 2010-2017 21

Figure 6: Immunoglobulins Market, The US, Revenue ($m), 2002-2017 22

Figure 7: Immunoglobulins Market, The US, Annual Cost of Therapy ($), 2002-2017 23

Figure 8: Immunoglobulins Market, Top Five Countries in Europe, Revenue ($m), 2010-2017 24

Figure 9: Immunoglobulins Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017 26

Figure 10: Immunoglobulins Market, Japan, Revenue, ($m), 2010-2017 27

Figure 11: Immunoglobulins Market, Japan, Annual Cost of Therapy, ($), 2010-2017 28

Figure 12: Immunoglobulins Market, Global, Primary Immunodeficiency, Revenue ($m), 2002-2017 30

Figure 13: Immunoglobulins Market, Global, Primary Immunodeficiency, Annual Cost of Therapy ($), 2002-2017 32

Figure 14: Immunoglobulins Market, Global, Primary Immunodeficiency, Epidemiology ('000), 2002-2017 33

Figure 15: Immunoglobulins Market, Global, Primary Immunodeficiency, Geographical Segmentation of Revenue, ($m), 2002-2017 37

Figure 16: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Revenue ($m), 2002-2017 40

Figure 17: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Annual Cost of Therapy ($), 2002-2017 41

Figure 18: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Epidemiology ('000), 2002-2017 42

Figure 19: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Geographical Segmentation of Revenue, ($m), 2002-2017 45

Figure 20: Immunoglobulins Market, Global, CLL, Revenue, ($m), 2002-2017 48

Figure 21: Immunoglobulins Market, Global, CLL, Annual Cost of Therapy ($), 2002-2017 49

Figure 22: Immunoglobulins Market, Global, CLL, Epidemiology ('000), 2002-2017 50

Figure 23: Immunoglobulins Market, Global, CLL, Geographical Segmentation of Revenue, ($m), 2002-2017 55

Figure 24: Immunoglobulins Market, Global, CIDP, Revenue, ($m), 2002-2017 57

Figure 25: Immunoglobulins Market, Global, CIDP, Annual Cost of Therapy ($), 2002-2017 58

Figure 26: Immunoglobulins Market, Global, CIDP, Epidemiology ('000), 2002-2017 59

Figure 27: Immunoglobulins Market, Global, CIDP, Geographical Segmentation of Revenue, ($m), 2002-2010 62

Figure 28: Immunoglobulins Market, Global, Myasthenia Gravis, Revenue, ($m), 2002-2017 64

Figure 29: Immunoglobulins Market, Global, Myasthenia Gravis, Annual Cost of Therapy ($), 2002-2017 65

Figure 30: Immunoglobulins Market, Global, Myasthenia Gravis, Epidemiology ('000), 2002-2017 66

Figure 31: Immunoglobulins Market, Global, Myasthenia Gravis, Geographical Segmentation of Revenue, ($m), 2002-2017 69

Figure 32: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Revenue, ($m), 2002-2017 71

Figure 33: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Annual Cost of Therapy ($), 2002-2017 72

Figure 34: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Epidemiology ('000), 2002-2017 74

Figure 35: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Geographical Segmentation of Revenue, ($m), 2002-2017 78

Figure 36: Immunoglobulins Market, Global, ITP, Revenue, ($m), 2002-2017 80

Figure 37: Immunoglobulins Market, Global, ITP, Annual Cost of Therapy ($), 2002-2017 81

Figure 38: Immunoglobulins Market, Global, ITP, Epidemiology ('000) 2002-2017 82

Figure 39: Immunoglobulins Market, Global, ITP, Geographical Segmentation of Revenue, ($m), 2002-2017 85

Figure 40: Immunoglobulins Market, Global, Market Share on the Basis of Revenue, (%), 2010 100

Figure 41: Immunoglobulins Market, SWOT Analysis of Baxter, 2010 101

Figure 42: Immunoglobulins Market, SWOT Analysis for Biotest, 2010 102

Figure 43: Immunoglobulins Market, SWOT Analysis for Bio Products Laboratory Limited, 2010 103

Figure 44: Immunoglobulins Market, SWOT Analysis of CSL Behring, 2010 104

Figure 45: Immunoglobulins Market, SWOT Analysis of Kedrion, 2010 105

Figure 46: Immunoglobulins Market, SWOT Analysis of LFB, 2010 105

Figure 47: Immunoglobulins Market, SWOT Analysis of Octapharma, 2010 106

Figure 48: Immunoglobulins Market, SWOT Analysis of Talecris, 2010 107

Figure 49: Immunoglobulins Market, SWOT Analysis of Grifols, 2010 108

Figure 50: Immunoglobulins Market, Global Strategic Consolidations Landscape, By Deal Type, 2004-2010 109

Figure 51: GBI Research Market Forecasting Model 119

Companies mentioned

Baxter International Inc.

Biotest

Bio Products Laboratory Ltd.

CSL Behring LLC

Kedrion S.p.A.

LFB S.A.

Octapharma AG

Talecris Biotherapeutics Holdings Corp

Grifols S.A.

To order this report:

Pathology Industry: Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com